D2-02: Excision repair cross complementing 6 (ERCC6) single nucleotide polymorphism (SNP) and outcome to gemcitabine(gem)/cisplatin(cis) or docetaxel(doc)/cis in stage IV non-small-cell lung cancer (NSCLC) patients (p)